Complete Commercialization

The Only Complete Commercialization Solution in the Industry

Let’s face it…It’s hard to launch a product in today’s environment. The reality is companies spend >$125MM over three years leading up to launch and 66% of drugs still don’t meet launch expectations. This looming risk, echoed by general industry pressures, leaves developers and investors alike looking for more advanced commercialization options that effectively maximize their pipelines.

We are committed to:

  • delivering more value than traditional licensing or launching on your own.
  • activating a complete, ready-to-deploy, high-performance commercialization and distribution engine.
  • accelerating your product from early development to marketing, effectively impacting patient outcomes and beyond.

We celebrate when you and your company capture full revenue potential without the added risk of diluting company value. See how others are using this new model effectively; download “The New Gold Standard of Drug Commercialization.”


EVERSANA COMPLETE Commercialization

Imagine not having to risk building an expensive infrastructure – because we have built a foundation you can customize for your product needs. Activate a complete, ready-to-deploy, high-performance commercialization and distribution engine today!


Recent Commercialization Partnerships

Iterum Therapeutics and EVERSANA partner to Support Oral Sulopenem Launch

Iterum Therapeutics, a clinical-stage pharmaceutical company focused on developing next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community and hospital settings, it has engaged EVERSANA™, to immediately initiate pre-launch activities, followed by planned commercialization services after the anticipated decision by the FDA in July 2021,. Learn More.

Humanigen and EVERSANA to Launch and Commercialize Lenzilumab for the Treatment of COVID-19

Humanigen, a clinical-stage biopharmaceutical company focused on preventing and treating an immune hyper-response called cytokine storm with its lead drug candidate lenzilumab™, chose EVERSANA  as their partner to make lenzilumab available to hospitalized and hypoxic COVID-19 patients in the event that an Emergency Use Authorization is issued from the U.S. Food and Drug Administration (FDA) and subsequent BLA. Read the full story

EVERSANA shares our tireless commitment to patients,” said Cameron Durrant, MD, MBA, chief executive officer of Humanigen. “We’ve matched our dedication to research and development in COVID-19 with a proven commercialization partner to ensure lenzilumab will reach patients quickly and efficiently following a potential EUA.



MacroGenics and EVERSANA Announce Agreement to Support the Potential Launch and Commercialization of Margetuximab

MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that it has partnered with EVERSANA to commercialize margetuximab in the United States, if approved. Read The Full Story

We are excited to partner with EVERSANA and leverage their integrated commercial services to efficiently launch margetuximab. We have been working closely with EVERSANA to fully align our commercialization strategies to educate healthcare providers and ensure patient access to margetuximab, while maintaining MacroGenics’ cash runway to fund our broader portfolio.”

Palette Life Sciences Chooses EVERSANA to Support US Commercialization of Solesta™

EVERSANA to enhance market access, commercialization, and distribution activities of Solesta™ in the United States. Read the Full Story

“We have a remarkable opportunity to make a positive impact on the lives of millions of people worldwide. Solesta is an effective therapy that deserves the right commercial strategy to improve awareness among caregivers, enhance market access for patients, and provide important physician support services. These initiatives allow us the opportunity to drive a positive long term quality of life impact for those who are suffering every day. We are certain that EVERSANA has the right capabilities and team to meet the needs of our stakeholders,”

 James Leech, Head of Strategy & Corporate Development, Palette Life Sciences

Evoke Pharma Enters Commercialization Agreement with EVERSANA for Gimoti™

EVERSANA to commercialize and distribute Gimoti in the U.S.  EVERSANA will utilize its internal sales organization along with other commercial functions for market access, marketing, distribution and patient support services. Read the full story

We are excited to partner with EVERSANA, which will allow us to efficiently and rapidly prepare to commercialize Gimoti without the need to invest in a large corporate infrastructure and build out a sales force. Under the agreement, we will leverage EVERSANA’s integrated suite of capabilities, including highly experienced personnel with expertise in all key facets of pharmaceutical product commercialization.

Dave Gonyer, President and CEO of EVOKE

Zosano Pharma Partners with EVERSANA to Launch and Commercialize Qtrypta™

EVERSANA, to commercialize and distribute Qtrypta™ in the United States. EVERSANA will utilize its internal sales force, distribution networks, patient services hub and market access capabilities to support the launch and commercialization of Qtrypta™. Read the full story.

“We are thrilled to partner with EVERSANA and, upon potential approval, look forward to leveraging its established sales force, distribution networks and market access capabilities to support the launch and commercialization of our innovative therapy for the acute treatment of migraine. With this collaboration, we now have access to a comprehensive commercial organization without the significant expense and time that would have been required to build our own infrastructure. We and EVERSANA have been working closely to ensure our commercialization strategies are aligned and fully supported with the appropriate resources to get this potential new therapy into the hands of patients who are in need of it.”

Steven Lo, President and CEO of Zosano

Predictable Commercial Success

Complete, full-scale, customizable infrastructure amplified by top industry launch leaders

Engineered to:

  • optimize the launch of precommercial assets
  • capture full revenue potential through maturity

Revolutionary, nontraditional financial deal structures provide flexibility of terms and options

Built to:

  • provide an alternative to traditional and more common strategies, such as selling it, out-licensing or going at it alone
  • reduce up-front cash investments necessary to launch
  • maximize revenue potential and minimize financial risk

Valuable assets demand integrated, predictive and actionable data to maximize growth potential

Empowered to:

  • maximize the ROI of data and analytic investments
  • enhance decision-making
  • create a seamless patient journey and positively impact outcomes

PM360 Magazine recognized EVERSANA™ COMPLETE COMMERCIALIZATION as one of the best in the industry.

PM360s Annual Innovation Issue, December 2020, recognizes EVERSANA™ COMPLETE COMMERCIALIZATION as an innovative strategy that is pushing pharma forward and achieving improved results for providers and patients.  The Annual Innovation Issue was established in 2011 to provide pharma with its first-ever guide to the life sciences industry’s latest advancements.

Read the full story on

Contact us to discuss how your asset can immediately benefit from COMPLETE COMMERCIALIZATION.